In sum, our study not only suggests ZFX is a potentially useful predictor that could improve current methods for prognostic assessment of stage II/III CRC patients, but also that targeting ZFX is be a promising therapeutic approach in CRC patients. This evidence concerns the gene ZFX and colorectal carcinoma.